ETHINYLESTRADIOL/DROSPIRENONE DAILY STADA 0.02 mg/3 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Etinilestradiol/Drospirenona Daily Stada 0.02 mg/3 mg film-coated tablets EFG

Read this entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Important things to know about combined hormonal contraceptives (CHCs):

• They are one of the most reliable reversible contraceptive methods if used correctly.
• They slightly increase the risk of having a blood clot in the veins and arteries, especially in the first year or when you start using a combined hormonal contraceptive again after a break of 4 weeks or more.
• Be alert and talk to your doctor if you think you might have symptoms of a blood clot (see section 2 “Blood clots”).

Contents of the Package Leaflet

1. What is Etinilestradiol/Drospirenona Daily Stada and what is it used for
2. What you need to know before you start taking Etinilestradiol/Drospirenona Daily Stada
   • Do not take Etinilestradiol/Drospirenona Daily Stada
   • Warnings and precautions
   • Blood clots
   • Etinilestradiol/Drospirenona Daily Stada and cancer
   • Bleeding between menstrual periods
   • What to do if you do not have your period during the placebo phase
   • Taking Etinilestradiol/Drospirenona Daily Stada with other medicines
   • Etinilestradiol/Drospirenona Daily Stada with food and drink
   • Laboratory tests
   • Pregnancy, breastfeeding, and fertility
   • Driving and using machines
   • Important information about some of the ingredients of Etinilestradiol/Drospirenona Daily Stada

1. How to take Etinilestradiol/Drospirenona Daily Stada
   • Preparation of the blister
   • • When you can start with the first blister
     • If you take more Etinilestradiol/Drospirenona Daily Stada than you should
     • If you forget to take Etinilestradiol/Drospirenona Daily Stada
     • What to do in case of severe nausea or diarrhea
     • Delayed menstrual period: what you should know
     • Change of the first day of your menstrual period: what you should know
     • If you stop taking Etinilestradiol/Drospirenona Daily Stada

1. Possible side effects
2. Storage of Etinilestradiol/Drospirenona Daily Stada
3. Contents of the pack and further information

1. What is Etinilestradiol/Drospirenona Daily Stada and what is it used for

Etinilestradiol/drospirenona is a contraceptive and is used to prevent pregnancy.

Each of the 21 active pink tablets contains a small amount of two different female hormones, called etinilestradiol and drospirenona.

The 7 white tablets do not contain active ingredients and are called placebo tablets.

Contraceptives that contain two hormones are called “combined” contraceptives.

2. What you need to know before taking Etinilestradiol/Drospirenona Daily Stada

General considerations

Before starting to use etinilestradiol/drospirenona, you should read the information about blood clots in section 2. It is especially important that you read the symptoms of a blood clot (see section 2 "Blood clots").

Before starting to take etinilestradiol/drospirenona, your doctor will ask you some questions about your personal and family medical history. Your doctor will also measure your blood pressure and, depending on your state of health, may perform other tests.

In this prospectus, several situations are described in which you should interrupt the use of etinilestradiol/drospirenona, or in which the effect of etinilestradiol/drospirenona may decrease. In such situations, you should not have sexual intercourse or should take additional non-hormonal contraceptive precautions, such as using a condom or another barrier method.

Do not use the rhythm method or the temperature method. These methods may not be reliable since etinilestradiol/drospirenona alters the monthly changes in body temperature and cervical mucus.

Ethinylestradiol/drospirenona, like other hormonal contraceptives, does not protect against HIV infection (AIDS) or any other sexually transmitted disease.

DO NOT TAKE Etinilestradiol/Drospirenona Daily Stada

You should not use etinilestradiol/drospirenona if you have any of the conditions listed below. Inform your doctor if you have any of the conditions listed below. Your doctor will discuss with you what other form of contraception would be more suitable.

• If you have (or have ever had) a blood clot in a blood vessel in your legs (deep vein thrombosis, DVT), in your lungs (pulmonary embolism, PE), or in other organs.
• If you know you have a disorder that affects blood clotting: for example, protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden, or antiphospholipid antibodies.
• If you need an operation or if you spend a long time without getting up (see section "Blood clots").
• If you have ever had a heart attack or a stroke.
• If you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be the first sign of a heart attack) or a transient ischemic attack (TIA, temporary stroke symptoms).

• If you have any of the following diseases that may increase your risk of forming a blood clot in the arteries:

• severe diabetes with blood vessel damage.
• very high blood pressure.
• very high levels of fat in the blood (cholesterol or triglycerides).
• a condition called hyperhomocysteinemia.

• If you have (or have ever had) a type of migraine called "migraine with aura".
• If you have (or have ever had) a liver disease and your liver function has not yet returned to normal.
• If your kidneys do not work well (renal failure).
• If you have (or have had) a tumor in the liver.
• If you have (or have had), or if you suspect you have breast cancer or cancer of the genitals.
• If you have vaginal bleeding, whose cause is unknown.
• If you are allergic to ethinylestradiol or drospirenona, or to any of the other components of ethinylestradiol/drospirenona (see section 6). This may manifest with itching, rash, or inflammation.
• If you have Hepatitis C and are taking medications that contain ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir (see also the section "Taking Etinilestradiol/Drospirenona Daily Stada with other medications").

Warnings and precautions

In some situations, you will need to be particularly careful while using ethinylestradiol/drospirenona or any other combined hormonal contraceptive, and it may be necessary for your doctor to perform regular check-ups.

Tell your doctor if you suffer from any of the following conditions:

If the condition develops or worsens while you are using ethinylestradiol/drospirenona, you should also inform your doctor.

BLOOD CLOTS

The use of a combined hormonal contraceptive like ethinylestradiol/drospirenona increases your risk of developing a blood clot compared to not using it. In rare cases, a blood clot can block blood vessels and cause serious problems.

Blood clots can form:

• In the veins (this is called "venous thrombosis", "venous thromboembolism", or VTE).
• In the arteries (this is called "arterial thrombosis", "arterial thromboembolism", or ATE).

Recovery from blood clots is not always complete. In rare cases, there can be serious long-term effects or, very rarely, they can be fatal.

It is essential to remember that the overall risk of a harmful blood clot due to ethinylestradiol/drospirenona is small.

HOW TO RECOGNIZE A BLOOD CLOT

Seek urgent medical attention if you notice any of the following signs or symptoms.

BLOOD CLOTS IN A VEIN

What can happen if a blood clot forms in a vein?

• The use of combined hormonal contraceptives has been associated with an increased risk of blood clots in the veins (venous thrombosis). However, these side effects are rare. They occur more frequently in the first year of use of a combined hormonal contraceptive.
• If a blood clot forms in a vein in the leg or foot, it can cause deep vein thrombosis (DVT).
• If a blood clot moves from the leg and lodges in the lung, it can cause a pulmonary embolism.
• In very rare cases, a clot can form in a vein of another organ, such as the eye (retinal vein thrombosis).

When is the risk of a blood clot in a vein higher?

The risk of a blood clot in a vein is higher during the first year in which you take a combined hormonal contraceptive for the first time. The risk may also be higher if you start taking a combined hormonal contraceptive (the same medication or a different one) after an interruption of 4 weeks or more.

After the first year, the risk decreases, but it is always slightly higher than if you were not taking a combined hormonal contraceptive.

When you stop taking ethinylestradiol/drospirenona, your risk of a blood clot returns to normal within a few weeks.

What is the risk of a blood clot?

The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.

The overall risk of a blood clot in the leg or lung (DVT or PE) with ethinylestradiol/drospirenona is small.

• Out of 10,000 women who do not use a combined hormonal contraceptive and are not pregnant, about 2 will develop a blood clot in a year.
• Out of 10,000 women who use a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate, about 5-7 will develop a blood clot in a year.
• Out of 10,000 women who use a combined hormonal contraceptive that contains drospirenona, such as ethinylestradiol/drospirenona, between 9 and 12 women will develop a blood clot in a year.
• The risk of a blood clot will depend on your personal history (see "Factors that increase your risk of a blood clot" below).

Factors that increase your risk of a blood clot in a vein

The risk of a blood clot with ethinylestradiol/drospirenona is small, but some conditions increase the risk. Your risk is higher:

• If you are overweight (body mass index or BMI over 30 kg/m2).
• If any of your close relatives have had a blood clot in the leg, lung, or other organ at a young age (i.e., before the age of about 50). In this case, you may have a hereditary blood clotting disorder.
• If you need an operation or spend a long time without getting up due to an injury or illness, or if you have a leg in a cast. You may need to stop using ethinylestradiol/drospirenona several weeks before surgery or while you have reduced mobility. If you need to stop using ethinylestradiol/drospirenona, ask your doctor when you can start using it again.
• As you get older (especially above about 35 years).
• If you have recently given birth.

The risk of a blood clot increases with the number of conditions you have.

Long-haul flights (more than 4 hours) may temporarily increase the risk of a blood clot, especially if you have any of the other risk factors listed.

It is essential to inform your doctor if you suffer from any of the above conditions, even if you are not sure. Your doctor may decide that you should stop using ethinylestradiol/drospirenona.

If any of the above conditions change while you are using ethinylestradiol/drospirenona, for example, a close relative experiences a thrombosis without a known cause, or you gain a lot of weight, inform your doctor.

BLOOD CLOTS IN AN ARTERY

What can happen if a blood clot forms in an artery?

Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.

Factors that increase your risk of a blood clot in an artery

It is essential to note that the risk of a heart attack or stroke due to ethinylestradiol/drospirenona is very small, but it can increase:

• With age (above about 35 years).
• If you smoke. When using a combined hormonal contraceptive like ethinylestradiol/drospirenona, you are advised to stop smoking. If you are unable to stop smoking and are over 35 years old, your doctor may advise you to use a different type of contraceptive.
• If you are overweight.
• If you have high blood pressure.
• If any of your close relatives have had a heart attack or stroke at a young age (less than about 50 years). In this case, you may also be at higher risk of having a heart attack or stroke.
• If you or any of your close relatives have high levels of fat in the blood (cholesterol or triglycerides).
• If you have migraines, especially migraines with aura.
• If you have a heart problem (valve disorder, heart rhythm disorder called atrial fibrillation).
• If you have diabetes.

If you have one or more of these conditions or if any of them are particularly severe, the risk of a blood clot may be further increased.

If any of the above conditions change while you are using ethinylestradiol/drospirenona, for example, you start smoking, a close relative experiences a thrombosis without a known cause, or you gain a lot of weight, inform your doctor.

Ethinylestradiol/Drospirenona Daily Stada and cancer

Women who use combined contraceptives have a slightly higher rate of breast cancer, but it is not known if this is due to the treatment. For example, it may be that more tumors are detected in women who take combined contraceptives because they are examined by a doctor more frequently. The incidence of breast tumors decreases gradually after stopping combined hormonal contraceptives.

It is essential to have your breasts checked regularly, and you should see your doctor if you notice any lump.

In rare cases, benign liver tumors, and even more rarely, malignant liver tumors, have been reported in users of hormonal contraceptives. See your doctor if you experience severe abdominal pain.

Psychiatric disorders

Some women who use hormonal contraceptives like ethinylestradiol/drospirenona have reported depression or a depressed mood. Depression can be severe and sometimes can induce suicidal thoughts. If you experience mood changes and depressive symptoms, contact your doctor for further medical advice as soon as possible.

Bleeding between menstrual periods

During the first few months of using ethinylestradiol/drospirenona, unexpected bleeding (bleeding outside of the placebo period) may occur.

3. How to take Etinilestradiol/Drospirenona Daily Stada

Each blister pack contains 21 active pink tablets and 7 white placebo tablets.

The two different types of colored etinilestradiol/drospirenona tablets are arranged in order. A blister pack contains 28 tablets.

Take one etinilestradiol/drospirenona tablet every day, with some water if necessary. You can take the tablets with or without food, but take them at approximately the same time every day.

Do not get confused about the tablet: take one pink tablet every day for the first 21 days, followed by one white tablet for the last 7 days. Then, start taking a new blister pack (21 pink tablets and 7 white tablets). This way, there is no break between two blister packs.

Due to the different composition of the tablets, it is necessary to start with the first tablet located in the upper left area and then take one tablet every day. To maintain the order, follow the direction of the arrows on the blister pack.

Preparing the blister pack

To help you follow the order of intake, each etinilestradiol/drospirenona blister pack contains 7 self-adhesive strips with the 7 days of the week. Choose the strip that starts with the day you take the first tablet. For example, if you take your first tablet on a Wednesday, use the strip that starts with "WED".

Then, stick the corresponding strip on the upper left part of the blister pack in the "Start" position. This way, there is a day of the week indicated above each tablet, and you can visually check if you have taken a particular tablet.

The arrows show the order in which you should take the tablets.

During the 7 days when you take the placebo tablets (the placebo days), you will usually start your period (also called withdrawal bleeding). Normally, your period will start on the second or third day after taking the last active pink tablet of etinilestradiol/drospirenona. Once you have taken the last white tablet, you should start the next blister pack, even if you have not yet finished your menstrual period. This means that you should start each blister pack on the same day of the weekthat you started the previous one, and your menstruation should take place during the same days every month.

If you take etinilestradiol/drospirenona Daily as indicated, you are also protected against pregnancy during the 7 days when you are taking the placebo tablets.

When can you start with the first blister pack

• If you have not used any hormonal contraceptive in the previous month

Start taking etinilestradiol/drospirenona Daily on the first day of your cycle (i.e., the first day of your menstrual period). If you start etinilestradiol/drospirenona Daily on the first day of your menstrual period, you will be immediately protected against pregnancy. You can also start on days 2-5 of your cycle, but you must use additional contraceptive methods (e.g., condoms) for the first 7 days.

• Switching from a combined hormonal contraceptive, vaginal ring, or patch

You can start taking etinilestradiol/drospirenona preferably on the day after taking the last active tablet (the last tablet that contains active ingredients) of your previous contraceptive, but no later than the day after the rest days of your previous contraceptive (or after taking the last inactive tablet of your previous contraceptive). When switching from a combined vaginal ring or patch, follow your doctor's recommendations.

• Switching from a progestin-only method (progestin-only pill, injection, implant, or intrauterine system)

You can switch from the progestin-only pill at any time (if it is an implant or intrauterine system, on the day of its removal; if it is an injectable, when the next injection is due), but in all cases, use additional contraceptive measures (e.g., condoms) for the first 7 days of tablet intake.

• After an abortion

Follow your doctor's recommendations.

• After having a child

You can start taking etinilestradiol/drospirenona between 21 and 28 days after having a child. If you start later, use a barrier method (e.g., condoms) for the first 7 days of etinilestradiol/drospirenona use.

If, after having a child, you have had sexual intercourse before starting to take etinilestradiol/drospirenona again, you must be sure you are not pregnant or wait for your next menstrual period.

• If you are breastfeeding and want to start taking etinilestradiol/drospirenona again after having a child

Read the section "Breastfeeding".

Ask your doctor if you are unsure when to start.

If you take more Etinilestradiol/Drospirenona Daily Stada than you should

No cases have been reported in which an overdose of etinilestradiol/drospirenona has caused serious harm.

The symptoms that may appear if you take many tablets at the same time may include feeling unwell or vomiting or vaginal bleeding. This bleeding may occur even in girls who have not yet had their first menstrual period, if they have accidentally taken this medication.

If you have taken too many etinilestradiol/drospirenona tablets, or discover that a child has taken them, consult your doctor or pharmacist.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 915 620 420, indicating the medication and the amount taken.

If you forget to take Etinilestradiol/Drospirenona Daily Stada

The tablets in the fourthrow of the blister pack are the placebo tablets. If you forget to take one of these tablets, it will have no effect on the effect of etinilestradiol/drospirenona. Discard the forgotten placebo tablet. If you forget to take an active pink tablet from the 1st, 2nd, or 3rdrow, do the following:

• If you are less than 12 hourslate in taking a tablet, the protection against pregnancy will not decrease. Take the tablet as soon as you remember and the following tablets at the usual time.
• If you are more than 12 hourslate in taking a tablet, the protection against pregnancy may be reduced. The more tablets you have forgotten, the higher the risk of becoming pregnant.

The risk of incomplete protection against pregnancy is greatest if you forget to take a pink tablet at the beginning or end of the blister pack. Therefore, you should follow these recommendations (see also the diagram below):

• Forgetfulness of more than one tablet in the blister pack

Consult your doctor.

• Forgetfulness of a tablet in week 1

Take the forgotten tablet as soon as you remember, even if it means taking two tablets at the same time. Continue taking the tablets at the usual time and use additional precautions, such as condoms, for the next 7 days. If you have had sexual intercourse in the week before forgetting the tablet, you may be pregnant. In this case, consult your doctor.

• Forgetfulness of a tablet in week 2

Take the forgotten tablet as soon as you remember, even if it means taking two tablets at the same time. Continue taking the tablets at the usual time. The protection against pregnancy will not decrease, and you do not need to take additional precautions.

• Forgetfulness of a tablet in week 3

You can choose between two options:

1. Take the forgotten tablet as soon as you remember, even if it means taking two tablets at the same time. Continue taking the tablets at the usual time. Instead of taking the white placebo tablets from this blister pack, discard them and start the next blister pack.

You will probably have your period at the end of the second blister pack, while taking the white placebo tablets, although you may experience light bleeding or spotting during the second blister pack.

1. You can also stop taking the active pink tablets and go directly to the 7 white placebo tablets (before taking the placebo tablets, you must note the day you forgot to take the tablet). If you want to start a new blister pack on the day you always start, take the placebo tablets for less than 7 days.

If you follow one of these two recommendations, you will remain protected against pregnancy.

• If you have forgotten to take a tablet and do not have bleeding during the placebo days, you may be pregnant. Contact your doctor before starting the next blister pack.

What to do in case of vomiting or severe diarrhea

If you vomit within 3-4 hours after taking an active pink tablet or suffer from severe diarrhea, there is a risk that the active ingredients of the contraceptive will not be fully absorbed by the body. The situation is almost equivalent to forgetting a tablet. After vomiting or diarrhea, take another active pink tablet from a reserve blister pack as soon as possible. If possible, take it within 12 hoursafter the usual time you take your contraceptive. If this is not possible or more than 12 hours have passed, follow the advice in the section "If you forget to take Etinilestradiol/Drospirenona Daily Stada".

Delaying your menstrual period: what you should know

Although it is not recommended, you can delay your menstrual period if you do not take the white placebo tablets from the fourth row and start taking a new etinilestradiol/drospirenona blister pack and finish it. You may experience light bleeding or spotting during the use of the second blister pack. Finish this second blister pack by taking the 7 white tablets from the 4th row. Then, start with the new blister pack.

You should ask your doctor for advice before deciding to delay your menstrual period.

Changing the first day of your menstrual period: what you should know

If you take the tablets as instructed, your menstrual period will start during the placebo week. If you want to change that day, reduce the number of placebo days – when you take the white placebo tablets – (but never increase them - 7 at most!). For example, if you normally start taking the placebo tablets on Fridays and want to change it to Tuesdays (3 days earlier), start a new blister pack 3 days earlier than usual. If you make the placebo interval very short (e.g., 3 days or less), you may not have bleeding during these days. Then, you may experience light bleeding or spotting.

If you are unsure how to proceed, consult your doctor.

If you stop treatment with Etinilestradiol/Drospirenona Daily Stada

You can stop taking etinilestradiol/drospirenona whenever you want. If you do not want to become pregnant, consult your doctor about other effective birth control methods. If you want to become pregnant, stop taking etinilestradiol/drospirenona and wait until your menstrual period before trying to become pregnant. This way, you can more easily calculate the estimated date of delivery.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. If you experience any adverse effect, especially if it is severe and persistent, or if you have any change in health that you think may be due to ethinylestradiol/drospirenone, consult your doctor.

All women who take combined hormonal contraceptives are at a higher risk of developing blood clots in the veins (venous thromboembolism (VTE)) or blood clots in the arteries (arterial thromboembolism (ATE)). For more detailed information on the different risks of taking combined hormonal contraceptives, see section 2 "What you need to know before taking Ethinylestradiol/Drospirenone Daily Stada".

The following is a list of adverse effects related to the use of ethinylestradiol/drospirenone.

Frequent Adverse Effects(may affect up to 1 in 10 women):

• emotional instability
• headache
• abdominal pain (stomach pain)
• acne
• breast pain, breast enlargement, painful or irregular menstrual periods
• weight gain

Uncommon Adverse Effects(may affect up to 1 in 100 women):

• candidiasis (vaginal infection)
• herpes simplex (on the lips)
• allergic reactions
• increased appetite
• depression, nervousness, sleep disorders
• tingling and numbness, dizziness
• vision problems
• irregular or unusually fast heartbeat
• blood clots (thrombosis) in a blood vessel in the legs or lungs (pulmonary embolism), high blood pressure, migraine, varicose veins
• sore throat
• nausea, vomiting, stomach and/or intestinal inflammation, diarrhea, constipation
• sudden swelling of the skin and/or mucous membranes (e.g., tongue or throat), and/or difficulty swallowing or urticaria potentially with difficulty breathing (angioedema), hair loss (alopecia), itching, skin rash, dry skin, seborrheic dermatitis
• neck pain, limb pain, muscle cramps
• bladder infection

• breast lumps (benign and cancerous), production of a milky liquid in the nipples, ovarian cysts, hot flashes, absence of menstruation, heavy menstrual bleeding, vaginal discharge, vaginal dryness, abdominal pain (pelvic), abnormal cervical smears (Pap smear or Pap staining), decreased interest in sex

• fluid retention, lack of energy, excessive thirst, increased sweating
• weight loss

Rare Adverse Effects(may affect between 1 and 10 in 1,000 women):

• asthma
• hearing problems
• erythema nodosum (characterized by painful red nodules on the skin)
• erythema multiforme (characterized by skin rash with target-shaped redness or ulcers)
• harmful blood clots in a vein or artery, for example:
• In a leg or foot (i.e., DVT)
• In a lung (i.e., PE)
• Heart attack
• Stroke
• Mild stroke or temporary symptoms similar to those of a stroke, called a transient ischemic attack (TIA)
• Blood clots in the liver, stomach/intestine, kidneys, or eye

The likelihood of having a blood clot may be higher if you have any other condition that increases this risk (see section 2 for more information on conditions that increase the risk of blood clots and symptoms of a blood clot)

Contact a doctor immediately if you experience any of the following symptoms of angioedema: swelling of the face, tongue, and/or throat, and/or difficulty swallowing or urticaria potentially with difficulty breathing (see also the "Warnings and Precautions" section)

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is an adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine

5. Storage of Ethinylestradiol/Drospirenone Daily Stada

Keep this medicine out of the sight and reach of children

This medicine does not require special storage conditions

Do not take this medicine after the expiration date that appears on the packaging after "CAD:". The expiration date is the last day of the month indicated

Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE Point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment

6. Package Contents and Additional Information

Composition of Ethinylestradiol/Drospirenone Daily Stada

Active Tablets:

The active ingredients are 0.02 mg of ethinylestradiol and 3 mg of drospirenone

The other components are:

Tablet core: lactose monohydrate, pregelatinized corn starch, povidone, sodium croscarmellose, polysorbate 80, magnesium stearate

Tablet coating: partially hydrolyzed polyvinyl alcohol, titanium dioxide (E-171), macrogol 3350, talc, yellow iron oxide (E-172), red iron oxide (E-172), black iron oxide (E-172)

Placebo Tablets:

Tablet core: lactose, povidone, magnesium stearate

Tablet coating: partially hydrolyzed polyvinyl alcohol, titanium dioxide (E-171), macrogol 3350, talc

Product Appearance and Package Contents

The active tablets are film-coated, round, pink tablets

The placebo tablets are film-coated, round, white tablets

Ethinylestradiol/Drospirenone Daily Stada is available in boxes of 1, 2, 3, 6, and 13 packages (blisters), each containing 28 tablets (21 active tablets and 7 placebo tablets)

Only some package sizes may be marketed

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Laboratory STADA, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern (Barcelona)

Spain

info@stada.es

Manufacturer

Laboratorios León Farma, S.A.

Pol. Ind. Navatejera

La Vallina s/n

24193-Villaquilambre (León)

Spain

Date of the Last Revision of this Prospectus: September 2022

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es